MSB Trading 2021 - paradigm shift, page-1903

Not sure if this has been referenced, but Sweden has unfortunately seen a sharp rise of MIS-C. In January it recorded 25 children with MIS-C and it seems like they have had 10 cases a month since winter.

This study is also interesting (https://pediatrics.aappublications.org/content/147/2/e2020024554) - children were evaluated with MIS-C and it found the symptoms were similar to Kawasaki-disease. The common treatment was intravenous immunoglobulin and steroids, as well as Azithromycin, Anakinra, infliximab, and hydroxychloroquine. No patients were given REM-L as I understand this was prior to the expanded access use in the States was granted.

I wonder if SI and the team have considered setting up (a small) shop in Sweden given their dramatic increase in MIS-C and the above studies conclusions on the effect of cardiac issues cf. Rem-L's magic in treating two children already in the States?

Surely it's time for the team to realise that there are other countries in the world other than the US...